RxDoctor Payments Data

Alexander Golberg, DO

Family Medicine · Brooklyn, NYNPI 1194739532

Payments from drug & device makers

$300in general payments, 2019–2025

Across 16 payments — averaging $18.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$64
  • AbbVie$56
  • Merz North America, Inc.$37
  • Amarin Pharma, Inc.$35
  • GSK$26
  • Nestle Healthcare Nutrition Inc.$25
  • plus $56 from 3 others

What the payments were for

  • Food & beverage$300100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$300 in reported general payments places this provider in the 45th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$466,424
Medicare patients
255
Services billed
5,388

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase39$34,098
MounjaroTirzepatide28$29,938
LinzessLinaclotide50$28,460
OzempicSemaglutide21$26,770
VascepaIcosapent Ethyl46$18,669
Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate15$18,575
DexilantDexlansoprazole32$17,011
NamzaricMemantine Hcl/Donepezil Hcl27$16,150
TrintellixVortioxetine Hydrobromide24$13,524
EliquisApixaban19$12,289
JanumetSitagliptin Phos/Metformin Hcl22$11,884
ByettaExenatide14$11,705
FemaraLetrozole11$9,629
Dexlansoprazole DrDexlansoprazole36$8,278
JanuviaSitagliptin Phosphate13$7,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess, Namzaric, Lumigan, Synthroid$56$87,901204 claims
Lilly USA, LLCMounjaro$21$29,93828 claims
Novo NordiskOzempic$64$26,77021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →